These studies demonstrated that detection of any of the panel-prespecified genetic alterations in tumor biopsy samples, as well as primary tumor sidedness, were predictive of clinical outcomes on anti-EGFR therapy15–18. This evidence concerns the gene EGFR and neoplasm.